<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648465</url>
  </required_header>
  <id_info>
    <org_study_id>HE 67/12</org_study_id>
    <secondary_id>2011-006160-48</secondary_id>
    <nct_id>NCT01648465</nct_id>
  </id_info>
  <brief_title>Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors</brief_title>
  <official_title>Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of everolimus administered as
      a first-line treatment in newly-diagnosed patients with advanced or inoperable
      Gastrointestinal (GI) or pancreatic neuroendocrine tumors.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 6, 2012</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>15 month PFS (Progression-Free Survival) rate</measure>
    <time_frame>15 months</time_frame>
    <description>To determine the rate of PFS patients at 15 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Defined as the time from the date of enrollment to the date of 1st radiologically documented disease progression or disease related death,assessed up to 36 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Defined as the time from the date of enrollment to the date of death from any cause,assessed up to 36 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of best response to treatment and the time to best response achievement</measure>
    <time_frame>Defined as the period from the date of treatment initiation to best response observation date througout the study, assessed up to 15 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety</measure>
    <time_frame>Assessment of adverse events will be performed every 28 days (per cycle) during treatment, assessed up to 16 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of biologic markers with disease progression</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Gastrointestinal Tumors</condition>
  <condition>Pancreatic Tumors</condition>
  <condition>Gastrointestinal Neuroendocrine Tumors</condition>
  <condition>Pancreatic Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, aged ≥ 18 years of age.

          2. Newly diagnosed patients with biopsy-proven well or moderately differentiated advanced
             (metastatic or unresectable) GI or pancreatic neuroendocrine tumor.

          3. Measurable disease based on RΕCIST 1.1 using a triphase CT scan or multi-phase MRI
             scan.

          4. Patients with a ki-67 measurement &lt;20% prior to their enrollment to the study.

          5. Performance status 0-2 on the WHO scale.

          6. Adequate bone marrow function as shown by:ANC ≥ 1.5 x 10^9/L,Platelets ≥ 100 x
             10^9/L,Hemoglobin &gt; 9 g/dL.

          7. Adequate liver function as shown by:Serum bilirubin ≤ 1.5 x ULN,ALT/SGPT and AST/SGOT
             ≤ 2.5 x ULN (ή ≤ 5 x ULN in patients with known liver metastases),INR &lt; 1.3 (INR &lt; 3
             in patients treated with anticoagulants).

          8. Adequate renal function as shown by: serum creatinine ≤ 1.5 x ULN.

          9. Fasting serum cholesterol ≤ 300 mg/dL or ≤ 7.75 mmol/L and fasting triglycerides ≤ 2.5
             x ULN. Note: In case one or both the above upper limits are exceeded, patient
             enrollment can only be performed upon proper antilipidemic treatment initiation.

         10. Women of childbearing potential, with a negative serum or urine pregnancy test within
             48 hours prior to first study treatment administration.

         11. Signed informed consent form obtained before any trial related activity, including the
             screening phase, according to the applicable law and ICH/GCP requirements.

         12. Signed informed consent for the use of biological and genetic material

        Exclusion Criteria:

          1. Patients with poorly differentiated or undifferentiated GI or pancreatic
             neuroendocrine carcinoma.

          2. Previous or concurrent cytotoxic chemotherapy, immunotherapy or radiotherapy.

          3. Hepatic artery embolization or cryoablation of hepatic metastasis within 1 month of
             study enrollment.

          4. Prior therapy with mTOR inhibitors (for example sirolimus, temsirolimus, everolimus).

          5. Patients receiving chronic treatment with corticosteroid immunosuppressives.

          6. Uncontrolled diabetes mellitus as defined by fasting serum glucose &gt; 1.5 x ULN.

          7. Patients who have any severe and/or uncontrolled medical conditions such as:

               -  unstable angina pectoris, symptomatic congestive heart failure NYHA class II,
                  III, IV, myocardial infarction ≤ 6 months prior to enrollment, serious
                  uncontrolled cardiac arrhythmia (LVEF &lt; 50 %)

               -  active or uncontrolled severe infection

               -  cirrhosis, chronic active hepatitis, chronic persistent hepatitis or inadequate
                  hepatic function (ALT/SGPT and AST/SGOT &gt; 5 x ULN)

               -  inadequate bone marrow (ANC &lt; 1.5 x 10^9/L, platelets &lt; 100 x 10^9/L, hemoglobin
                  ≤ 9 g/dL) or renal failure (serum creatinine &gt; 1.5 x ULN

               -  severely impaired lung function (patients needing oxygen support).

          8. Active bleeding diathesis or on oral treatment with vitamin K antagonists (apart from
             low-dose coumadine).

          9. Performance status ≥ 3 on the WHO scale.

         10. Patients with a known history of HIV seropositivity. Screening for HIV infection at
             baseline is not required.

         11. No other prior or concurrent malignancy is allowed except for the following:
             adequately treated basal cell or squamous cell skin cancer, or treated in situ cancer
             of the cervix, or any other cancer from which the patient has been disease free for ≥
             3 years.

         12. Patients within 28 days post-major surgery (e.g. intra-thoracic, intrabdominal or
             intra-pelvic), open biopsy, or significant traumatic injury to avoid wound healing
             complications. Minor procedures and percutaneous biopsies or placement of vascular
             access device require 7 days prior to study entry. Note: Patients must have recovered
             from the acute effects of surgery prior to enrollment.

         13. Female patients who are pregnant or nursing (lactating).

         14. Adults with reproductive potential who are not using effective birth control methods.
             If barrier contraceptive measures are being used, these must be continued throughout
             the study by both sexes.

         15. Patients participating in another clinical trial or receiving an investigational drug.

         16. Patients unwilling or unable to comply with the protocol at the investigator's
             discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Koumarianou, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>4th Dept of Internal Medicine, University Hospital &quot;Attikon&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11522</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, 251 General Airforce Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Dept of Internal Medicine, General Hospital of Athens &quot;Hippokratio&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Dept of Internal Medicine, Propaedeutic, University Hospital &quot;Attikon&quot;</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4th Dept of Internal Medicine, University Hospital &quot;Attiko&quot;</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital</name>
      <address>
        <city>Athens</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Dept of Medical Oncology, Metropolitan Hospital</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, Ioannina University Hospital</name>
      <address>
        <city>Ioannina</city>
        <zip>45110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Oncology, Dept of Internal Medicine, University Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, Papageorgiou General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, Thermi Clinic</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>unresectable</keyword>
  <keyword>well or moderately differentiated</keyword>
  <keyword>advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

